Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Glatiramer acetate treatment negatively regulates type I interferon signaling.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Fingolimod is a potential novel therapy for multiple sclerosis.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Fourth Cooperative Meeting of Consortium of MS Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union

Pages